menu search

“no such thing as too big to fail in crypto” - aag ceo, jack vinijtrongjit

Finance Magnates spoke with Jack Vinijtrongjit, CEO of AAG for his perspective on Web3’s adoption, regulation, and a wide range...

December 13, 2022, 1:59 pm

Kulr technology group launches cellcheck battery monitoring system on microsoft's azure cloud service

KULR Technology Group Inc (NYSE:KULR) announced that its CellCheck Battery Monitoring System is now running on the Azure cloud computing service by Mi...

December 13, 2022, 9:32 am

Keyera: growth, dividends, value

Keyera is a midstream energy company focused on natural gas and natural gas liquids in Western Canada. This article examines their business model, div...

December 13, 2022, 6:30 am

Molecular partners presents new preclinical data supporting its mp0533 darpin t-cell engager for the treatment of aml

New data indicates potential to expand the therapeutic window and improve safety compared to existing T...

December 13, 2022, 12:00 am

Cross country healthcare: volatile earnings, but a low p/e - shares at a key technical spot

Healthcare providers have been a source of relative safety this year, but the group has given back some...

December 12, 2022, 4:14 pm

Cardiol therapeutics kicks off a multi-center phase ii pilot study of cardiolrx for the treatment of recurrent pericarditis

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc revealed that it had initiated a Phase II open-label pilot study to investigate the ...

December 12, 2022, 11:59 am

Coinbase 'stands apart' but 'crypto winter' risks prompt caution on stock

KeyBanc Capital Markets analyst Alex Markgraff initiated coverage of Coinbase Global Inc. shares COIN, -6.00% with a sector-weight rating Sunday, writ...

December 12, 2022, 9:20 am

Poolbeg pharma's new flu jab safely completes first clinical trial

Poolbeg Pharma said it had completed the first clinical trial for its new flu jab POLB 001 with no safety ...

December 12, 2022, 2:58 am

Msa safety: looks dicey due to demand uncertainty and relative overvaluation

Supply chain disruptions in electronics can undermine the benefits of pricing hikes. A muted industry activity index and a slowing global economy can ...

December 12, 2022, 2:57 am

Cogent biosciences announces positive updated clinical data from ongoing phase 2 apex trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (advsm)

– 89% ORR in TKI-therapy naïve patients; 73% ORR in all evaluable patients with 27-week median follow-up – Rapid and deep responses seen includin...

December 11, 2022, 10:30 pm

Vincerx pharma presents preclinical data on vip943 in acute myeloid leukemia models at the 64th american society of hematology annual meeting 2022

Vincerx’s proprietary payload and linker technology and VIP943, a novel anti-CD123 antibody drug conjugate (ADC), demonstrated superiority with sign...

December 11, 2022, 3:05 pm

Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion

– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...

December 10, 2022, 11:30 pm

Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion

– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...

December 10, 2022, 11:30 pm

Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion

– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...

December 10, 2022, 11:30 pm

Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion

– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...

December 10, 2022, 11:30 pm

Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion

– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...

December 10, 2022, 11:30 pm

Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion

– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...

December 10, 2022, 11:30 pm

Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion

– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...

December 10, 2022, 11:30 pm

Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion

– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...

December 10, 2022, 11:30 pm

Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion

– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...

December 10, 2022, 11:30 pm


Search within

Pages Search Results: